Ex Vivo Perfusion With Methylprednisolone Attenuates Brain Death-induced Lung Injury in Rats

Judith E. van Zanden, MD,1 Henri G.D. Leuvenink, PhD,1 Erik A.M. Verschuuren, MD, PhD,2 Zwanida J. Veldhuis, BSc,1 Petra J. Ottens, BSc,1 Michiel E. Erasmus, MD, PhD,3 and Maximilia C. Hottenrott, MD, PhD1,4

INTRODUCTION

Despite an increase in donor lung procurement rates over the last years, half of the cadaveric lung donors are considered unsuitable for transplantation.1 One of the main factors that contribute to decreased lung quality is lung damage caused by pathophysiological changes upon brain death (BD). With the onset of BD, a catecholamine storm occurs and a proinflammatory environment is created, which eventually leads to pulmonary edema formation.2

A newly developed strategy to increase the yield of lung donation is ex vivo lung perfusion (EVLP). This technique provides an opportunity to assess and test donor lungs with questionable quality, in a safe setting for the potential recipient. In addition, EVLP might serve as a promising treatment platform to improve donor lung quality.3

Background. The onset of brain death (BD) leads to the deterioration of potential donor lungs. Methylprednisolone is considered to increase lung oxygenation capacity and enhance the procurement yield of donor lungs, when applied in situ, during donor management. However, whether BD-induced lung damage is ameliorated upon treatment with methylprednisolone during acellular ex vivo lung perfusion (EVLP), remains unknown. We aimed to investigate whether the quality of lungs from brain-dead donors improves upon methylprednisolone treatment during EVLP.

Methods. Rat lungs were randomly assigned to 1 of 3 experimental groups (n = 8/group): (1) healthy, directly procured lungs subjected to EVLP; (2) lungs from brain-dead rats subjected to cold storage and EVLP; and (3) lungs from brain-dead rats subjected to cold storage and EVLP with 40 mg methylprednisolone added to the perfusate. Ventilation and perfusion parameters, histology, edema formation, metabolic profile, and inflammatory status of lungs were investigated.

Results. Methylprednisolone treated lungs from brain-dead donors improved positive inspiratory pressures needed to maintain tidal volumes of 7 mL/kg of body weight, which was 25.6 ± 5.8 cm H2O in untreated lungs and 18.0 ± 3.0 cm H2O in methylprednisolone treated lungs, after 6h EVLP. Furthermore, dynamic lung compliance increased upon methylprednisolone treatment, with values of 0.11 ± 0.05 mL/cm H2O versus 0.18 ± 0.04 mL/cm H2O after 6h of EVLP. Methylprednisolone treatment ameliorated the amount of lung edema, as corroborated by a reduction of 0.7 in the wet/dry ratio. Although glucose consumption levels were comparable, the BD-induced cumulative lactate production decreased from 0.44 ± 0.26 to 0.11 ± 0.16 mmol/L upon methylprednisolone treatment. Finally, BD-induced inflammatory status was reduced upon methylprednisolone treatment compared to untreated lungs from brain-dead donors, as reflected by lower proinflammatory gene expression levels of IL-1β, IL-6 and MCP-1, and IL-6 perfusate levels.

Conclusions. We showed that methylprednisolone treatment during EVLP attenuates BD-induced lung injury.
Methylprednisolone is considered to increase lung oxygenation capacity and enhance the procurement yield of donor lungs when applied in situ. Also, the anti-inflammatory properties of methylprednisolone might dampen the BD-induced immune response. Yet, the application of methylprednisolone treatment in the donor remains a subject of debate, mainly due to contradictory results on quality of abdominal organs. In some countries methylprednisolone treatment is recommended in all donors, whereas in other countries only potential lung donors are treated. Furthermore, negative side effects such as steroid-induced hyperglycemia may detrimentally affect organ function. In clinically applied EVLP, methylprednisolone is conventionally added to the acellular perfusate. However, whether BD-induced lung damage is ameliorated upon treatment with methylprednisolone during EVLP remains unknown.

We aimed to investigate whether quality of lungs from brain-dead donors improves upon methylprednisolone treatment during EVLP. To this end, we induced BD in rats, and after 3 h donor stabilization and 1 h cold storage (CS), we subjected the procured lungs to EVLP for 6 h, in which methylprednisolone was added to the perfusate or omitted.

**MATERIALS AND METHODS**

**Experimental Outline**

Lungs from donor rats were randomly assigned to 1 of 3 experimental groups (n = 8/group, Figure 1): (1) healthy, directly procured lungs subjected to EVLP; (2) lungs from brain-dead rats subjected to CS and EVLP; and (3) lungs from brain-dead rats subjected to CS and EVLP with 40 mg methylprednisolone added to the EVLP perfusate.

**Rats**

Male inbred Lewis rats (Harlan Laboratories, Melderslo, The Netherlands) with a weight of 350–450 g were used. Rats were fed standard rat chow ad libitum, and received humane care in compliance with the Principles of Laboratory Animal Care (NIH Publication No. 86-23, revised 1985) and the Dutch Law on Experimental Animal Care. The Institutional Animal Care and Use Committee of the University of Groningen provided consent for the experiment.

**BD Induction, Lung Procurement, and EVLP**

The BD procedure was adapted from the experimental BD model described by Kolkert et al. Briefly, rats were subcutaneously anesthetized with ketamine hydrochloride (75 mg/kg, Alfason B.V., Woerden, The Netherlands) and medetomidine (0.5 mg/kg, Orion Pharma, Mechelen, The Netherlands). Thereafter, anesthesia was continued with subcutaneous boluses of ketamine hydrochloride/medetomidine mixture administered every 15 min, at one-fourth of the initial dose. The right femoral vessels were cannulated for mean arterial pressure measurements and fluid administration. Mean arterial pressure was stabilized >80 mm Hg by administration of Hydroxyethyl starch (HAES sterile 100 g/L, Fresenius Kabi, Bad Homburg, Germany) and saline (Baxter B.V., Utrecht, The Netherlands), with a maximum of 2 mL HAES and saline per hour. A craniotomy was performed in prone position and a 4F Fogarty catheter (Edwards Lifesciences LLC, Irvine, CA) was inserted in the epidural space. Thereafter, rats were placed in supine position, tracheotomized, and intubated with a 14G polyethylene tube (Kliniject, KLINIKA Medical GmbH, Usingen, Germany). Lungs were pressure-regulated volume control ventilated (Babylog 8000 ventilator, Draeger, Luebeck, Germany).

Ventilation settings were as follows: tidal volume (VT) 7 mL/kg of body weight (BW), positive end-expiratory pressure (PEEP) 3 cm H2O, inspiratory/expiratory ratio 1:1, and fraction of inspired oxygen (FiO2) 0.5. Directly after intubation, a recruitment maneuver was performed. PEEP was increased to 15 cm H2O at a maximum positive inspiratory pressure (PIP) of 20 mm H2O. Respiratory rate was increased to 150/min for 10 min for preoxygenation before BD induction, and thereafter reduced to a frequency of 133/min. BD was induced by inflation of the Fogarty catheter over 60 s and confirmed by the absence of corneal reflexes 30 min after BD induction. Brain-dead rats were stabilized for 3 h. In group 1, the non-BD healthy control, femoral vessel cannulation was omitted and lungs were immediately procured after intubation.

Before lung procurement, the respiratory rate was reduced to 60 breaths/min followed by a recruitment maneuver as described before. A median laparothoracotomy was performed and 1000 IU heparin (Leo Pharma B.V., Amsterdam, The Netherlands) was injected into the right ventricle. The pulmonary artery was cannulated and lungs were flushed with Perfadex (XVIVO Perfusion, Gothenburg, Sweden) for 2 min on a pressure of 15 mm Hg. Thereafter, lungs were procured and cold-stored in Perfadex on ice for 1 h, with a PEEP of 5 cm H2O.

Next, lungs were placed on the EVLP platform. After initial recruitment, ventilation was continued with a VT of 4 mL/kg of BW and a respiratory rate of 60/min. PEEP was set at 5 cm H2O and FiO2 was 0.21. Lungs were reperfused at room temperature with Steen solution (XVIVO Perfusion, Gothenburg, Sweden) supplemented with 6 g BSA (Sigma-Aldrich, Zwijndrecht, The Netherlands) and 0.12 g cefuroxime.
During EVLP, glucose levels of the perfusate in the reservoir compliance (C_{dyn}) was calculated by the equation C_{dyn} = VT/ventilate with 7 mL of BW was noted over time. Dynamic lung function by the lung was calculated by Lactate = Lactate outflow – Lactate inflow. Subsequently, cumulative glucose consumption was increased to 1 and the perfusate was deoxygenated for 5 min with a gas mixture of 6% O_{2}, 8% CO_{2}, and 86% N_{2}. The water bath was started to gradually increase perfusate pressure to 9 mm Hg. The water bath was started to gradually increase perfusate temperature to 37 °C. In group 3, 40 mg methylprednisolone (40 mg/ml, Pfizer, Capelle aan den IJssel, The Netherlands) was added to the perfusate. The methylprednisolone dose was chosen to approach the dilution in the circulating perfusate as applied in clinical EVLP models. After 10 min of reperfusion, VT was increased to 7 mL/kg of BW and pressure and perfusion pressure to 12.5 mm Hg. Lungs were perfused for 6 h. During EVLP, glucose levels of the perfusate in the reservoir were measured and corrected with glucose solution (50 g/L, Baxter B.V.,) in the case of levels <9 mmol/L. PIP required to ventilate with 7 mL of BW was noted over time. Dynamic lung compliance (C_{dyn}) was calculated by the equation C_{dyn} = VT/(PIP – PEEP). Perfusion flow was determined by measuring the amount of out flowing perfusate over 1 min. Perfusate was collected at baseline, 15 min, 30 min, and subsequently every hour after the start of reperfusion. At the end of EVLP lungs were clamped with a PEEP of 10 cm H_{2}O and placed on ice. The right and left main bronchi were ligated and the right upper and lower lobe were snap-frozen in liquid nitrogen. The right middle lobe was used to determine the wet/dry (W/D) ratio and the left lung lobe was formalin-fixed and paraffin embedded.

**Oxygenation Capacity and Metabolic Profile of EVLP Lungs**

Blood gas analyses were performed (ABL90 blood gas analyzer) to measure oxygenation capacity, glucose, and lactate levels of ex vivo perfused lungs. Before sample taking, FiO_{2} was increased to 1 and the perfusate was deoxygenated for 5 min with a gas mixture of 6% O_{2}, 8% CO_{2}, and 86% N_{2}. Glucose consumption by the lung was calculated by the equation \Delta Glucose = Glucose_{outflow} – Glucose_{inflow}. Lactate production by the lung was calculated by \Delta Lactate = Lactate_{outflow} – Lactate_{inflow}. Subsequently, cumulative glucose consumption and lactate production were calculated over time.

**Lung Edema**

The severity of lung edema was investigated by the W/D ratio of the lung tissue. The right middle lung lobe was collected in an Eppendorf tube and weighed before and after drying for 24 h at 100 °C. The W/D ratio was calculated by the equation W/D ratio = (weight predrying – weight Eppendorf tube)/(weight postdrying – weight Eppendorf tube).

**Quantitative Reverse Transcription Polymerase Chain Reaction**

Quantitative reverse transcription polymerase chain reaction analyses were performed to detect proinflammatory gene expression levels in lungs. Total RNA was isolated from the snap-frozen lung tissue using Trizol (Invitrogen Life Technologies, Breda, The Netherlands), according to the manufacturer’s instructions. Integrity of total RNA was analyzed by gel electrophoresis and RNA was treated with DNaseI (Invitrogen) to remove genomic DNA. RNA was transcribed into cDNA by adding M-MLV Reverse Transcriptase (Invitrogen) in the presence of dNTPs (Invitrogen); after initial incubation with Oligo-dT primers (Invitrogen). Gene expression analyses were performed at mRNA level by TaqMan low-density array. Designed primer sets (Table 1) were loaded with 5 μL cDNA (2 ng/μL) and SYBR green (Applied Biosystems, Foster City, CA). Amplification and detection were performed with the ABI Prism 7900-HT Sequence Detection System, which measures SYBR green emission. The PCR reaction consisted of 40 cycles at 95 °C for 15 s and 60 °C for 60 s, after initiation for 2 min at 50 °C and 10 min at 95 °C. Dissociation curve analyses were performed to ensure amplification of specific products. All samples were measured in triplicate. Gene expressions were normalized to housekeeping genes Ppia and Eif2b1 and gene expression values were calculated by the ΔΔCt method. Protein levels of IL-6 in the EVLP perfusate were quantified by sandwich ELISA, according to manufacturer’s instructions (R&D systems, Abingdon, United Kingdom). Briefly, maxisorb 96-well plates were coated overnight with the capture antibody (4.0 μg/mL). After plates were blocked with reagent diluent for 1 h, and samples were incubated for 2 h. The detection antibody was diluted in reagent diluent and 2% heat-inactivated normal goat serum, to an end concentration of 400 μg/mL. After the detection antibody was incubated for 2 h, Streptavidin-Horseradish Peroxidase was added and incubated for 20 min in the dark. Substrate solution was incubated for 35 min in the dark, and thereafter, stop solution was added. Appropriate washing steps were applied between incubations, and all incubation steps were performed at room temperature. The amount of reacted substrate was measured at an optical density of 450 nm (VICTOR-3, 1420 multilabel counter, PerkinElmer, Waltham, MA).

**Lung Morphology**

Formalin-fixed and paraffin-embedded lung sections (4 μm) were stained with hematoxylin and eosin to assess lung morphology. Lung morphology was quantified based on a previously described lung injury score with inclusion of alveolar septal thickening. Per lung section, 10 snapshots were scored in a blinded manner on 400× magnification for 5 independent variables: (1) inflammatory cell influx in interstitium and alveolar space; (2) thickening of the alveolar septa; (3) intra-alveolar and extra-alveolar hemorrhage; (4) intra-alveolar edema; and (5) overinflation. The variables were scored from 0 to 4: 0 = negative, 1 = slight, 2 = moderate, 3 = high, and 4 = severe. Total lung morphology scores were calculated by the sum of the scored variables.

**Statistics**

Statistical analyses were performed with IBM SPSS Statistics 26 (IBM Corporation, New York, NY). Data from multiple observations over time were analyzed with mixed-model analyses of variance tests to analyze the effect of group and time on ventilation and perfusion parameters. As follow-up tests, 1-way analyses of variance's with post hoc Bonferroni tests were performed to test differences between groups at specific time points. To determine differences of dependent variables between multiple groups, Kruskal–Wallis tests were performed, followed by Mann–Whitney U post hoc tests. P values of <0.05 were considered statistically significant and results are presented as mean ± SD.

**RESULTS**

Methylprednisolone Treatment Beneficially Affects Lung Ventilation Performance of Lungs From Brain-dead Donors

Ventilation and perfusion parameters during EVLP were compared between groups to investigate whether
methylprednisolone affects performance of lungs procured from brain-dead donors. PIP required to maintain ventilation at a tidal volume of 7mL/kg of BW, showed an interaction between time and treatment group (P = 0.008). PIP increased over the perfusion period, and from 3.5h after reperfusion onward, this increase in PIP was higher in untreated lungs from brain-dead donors, than in healthy donor lungs (Figure 2A), with PIP levels of 25.6 ± 5.8cm H2O versus 17.1 ± 3.4cm H2O after 6h of EVLP (P = 0.005). Methylprednisolone treatment of lungs from brain-dead donors attenuated the BD-induced PIP increase to 18.0 ± 3.0 cm H2O (P = 0.012) after 6h of EVLP, comparable to values of healthy donor lungs (P = 1.000). Dynamic lung compliance values showed a main effect for time (P = 0.000) and treatment group (P = 0.021), yet no interaction between time and group was observed (P = 0.589, Figure 2B). Cdyn worsened over time, and from 4h after reperfusion onward, Cdyn values were lower in untreated lungs from brain-dead donors than in healthy donor lungs, with Cdyn values of 0.11 ± 0.05 mL/cm H2O versus 0.20 ± 0.05 mL/cm H2O after 6h of EVLP (P = 0.013). Methylprednisolone attenuated Cdyn decrease in lungs from brain-dead donors to 0.18 ± 0.04 mL/cm H2O after 6h of EVLP (P = 0.036), comparable to values of healthy donor lungs (P = 1.000). Nonetheless, no effect of time (P = 0.075) nor treatment group (P = 0.365) was observed in oxygenation status of donor lungs on EVLP, as reflected by the Pao2/FiO2 ratio (Figure 2C). Perfusion flow was observed in oxygenation status of donor lungs on EVLP, = 0.365)
effect of time (= 0.075) nor treatment group (P = 0.000). Qualitative evidence of edema is reduced in methylprednisolone treated lungs from brain-dead donors.

**Methylprednisolone Attenuates Lactate Production by Lungs From Brain-dead Donors**

Considering that pulmonary lactate production is increased in acute lung injury, we investigated the metabolic profile of ex vivo perfused lungs. The amount of cumulative glucose consumption was comparable in all 3 groups (P = 0.348, Figure 4A). In contrast, cumulative lactate production was higher by untreated lungs from brain-dead donors, than by healthy donor lungs (0.44 ± 0.26 mmol/L versus 0.14 ± 0.10 mmol/L, P = 0.014, Figure 4B). Methylprednisolone treatment decreased cumulative lactate production by lungs from brain-dead donors to 0.11 ± 0.16 mmol/L (P = 0.017), comparable to healthy donor lungs (P = 0.547). Taken together, these results suggest that a shift to anaerobic metabolism occurs in lungs from brain-dead donors, which is attenuated by methylprednisolone treatment during EVLP.

**Methylprednisolone Downregulates the BD-induced Proinflammatory Response**

Since the process of BD leads to a proinflammatory state of the donor and subsequently donor organs, we investigated the effect of methylprednisolone on proinflammatory gene expression levels of ex vivo perfused lungs (Figure 5A–E). The amount of cumulative glucose consumption was comparable in all 3 groups (P = 0.348, Figure 4A). In contrast, cumulative lactate production was higher by untreated lungs from brain-dead donors, than by healthy donor lungs (0.44 ± 0.26 mmol/L versus 0.14 ± 0.10 mmol/L, P = 0.014, Figure 4B). Methylprednisolone treatment decreased cumulative lactate production by lungs from brain-dead donors to 0.11 ± 0.16 mmol/L (P = 0.017), comparable to healthy donor lungs (P = 0.547). Taken together, these results suggest that a shift to anaerobic metabolism occurs in lungs from brain-dead donors, which is attenuated by methylprednisolone treatment during EVLP.

**Methylprednisolone Does Not Ameliorate Histological Lung Injury, Yet Reduces the Quantity of Edema Formation in Lungs From Brain-dead Donors**

Subsequently, we assessed whether lung morphology is affected by methylprednisolone treatment during EVLP. Overall histological evidence of lung injury was higher in lungs from brain-dead donors subjected to EVLP than healthy donor lungs subjected to EVLP (P = 0.012, Figure 3A-D). This was mainly the result of higher inflammatory cell influx in lungs from brain-dead donors than in lungs from healthy donors (P = 0.002). Qualitative evidence of edema formation in hematoxylin and eosin stained lung tissue was similar between groups (P = 0.798). However, quantitative measurements by means of W/D ratio showed that methylprednisolone reduced the amount of lung edema in lungs from brain-dead donors with 0.7 (5.5 ± 0.4 versus 6.2 ± 0.4, P = 0.013), even lower than healthy donor lungs (5.5 ± 0.4 versus 6.1 ± 0.3, P = 0.018). These results suggest that histological lung injury does not improve upon methylprednisolone treatment during EVLP, yet the amount of pulmonary edema is reduced in methylprednisolone treated lungs from brain-dead donors.

**TABLE 1. RT-qPCR primers**

| Primer | Gene | Forward primer | Reverse primer | Amplicon (bp) |
|--------|------|----------------|----------------|--------------|
| TNF-α  | Tumor necrosis | AGGCTGTGCTACATCATCAGTGA | TGACCCTAGGCGATTACA | 67 |
| IL-1β  | Interleukin-beta | AGGCTGCTGCTACATCATCAGTGA | TGACCCTAGGCGATTACA | 75 |
| IL-6   | Interleukin-6 | CCAACTTCCATGCTCTCTCTATG | TCTCACTTGTCAAGTGTGAT | 89 |
| MCP-1  | Monocyte chemoattractant protein-1 | CTTGAGATGTGAATGCTGACCATTA | AGCAAGTGCTGTGACTAGTGA | 78 |
| C3     | Central complement component 3 | CAGCCTGATGAAAGCTAGTCA | TCAAAATCATCGACACGCTCTAC | 96 |

RT-qPCR, quantitative reverse transcription polymerase chain reaction.

### Edema Formation in Lungs From Brain-dead Donors

**Methylprednisolone Does Not Ameliorate Histological Lung Injury, Yet Reduces the Quantity of Edema Formation in Lungs From Brain-dead Donors**

Subsequently, we assessed whether lung morphology is affected by methylprednisolone treatment during EVLP. Overall histological evidence of lung injury was higher in lungs from brain-dead donors subjected to EVLP than healthy donor lungs subjected to EVLP (P = 0.012, Figure 3A-D). This was mainly the result of higher inflammatory cell influx in lungs from brain-dead donors than in lungs from healthy donors (P = 0.002). Qualitative evidence of edema formation in hematoxylin and eosin stained lung tissue was similar between groups (P = 0.798). However, quantitative measurements by means of W/D ratio showed that methylprednisolone reduced the amount of lung edema in lungs from brain-dead donors with 0.7 (5.5 ± 0.4 versus 6.2 ± 0.4, P = 0.013), even lower than healthy donor lungs (5.5 ± 0.4 versus 6.1 ± 0.3, P = 0.018). These results suggest that histological lung injury does not improve upon methylprednisolone treatment during EVLP, yet the amount of pulmonary edema is reduced in methylprednisolone treated lungs from brain-dead donors.

**Methylprednisolone Attenuates Lactate Production by Lungs From Brain-dead Donors**

Considering that pulmonary lactate production is increased in acute lung injury, we investigated the metabolic profile of ex vivo perfused lungs. The amount of cumulative glucose consumption was comparable in all 3 groups (P = 0.348, Figure 4A). In contrast, cumulative lactate production was higher by untreated lungs from brain-dead donors, than by healthy donor lungs (0.44 ± 0.26 mmol/L versus 0.14 ± 0.10 mmol/L, P = 0.014, Figure 4B). Methylprednisolone treatment decreased cumulative lactate production by lungs from brain-dead donors to 0.11 ± 0.16 mmol/L (P = 0.017), comparable to healthy donor lungs (P = 0.547). Taken together, these results suggest that a shift to anaerobic metabolism occurs in lungs from brain-dead donors, which is attenuated by methylprednisolone treatment during EVLP.

**Methylprednisolone Downregulates the BD-induced Proinflammatory Response**

Since the process of BD leads to a proinflammatory state of the donor and subsequently donor organs, we investigated the effect of methylprednisolone on proinflammatory gene expression levels of ex vivo perfused lungs (Figure 5A–E). Overall, proinflammatory gene expressions were higher in lungs from brain-dead donors compared to healthy donor lungs. Nevertheless, significance was reached only in IL-1β gene expression (P = 0.002), in contrast to TNF-α (P = 0.085), IL-6 (P = 0.224), and MCP-1 (P = 0.277). Complement C3 gene expressions were similar between lungs from healthy donors and lungs from brain-dead donors (P = 0.749). Methylprednisolone downregulated gene expression levels of IL-1β (P = 0.009), IL-6 (P = 0.006), and MCP-1 (P = 0.002) in lungs from brain-dead donors, when compared with untreated lungs from brain-dead donors. To confirm the anti-inflammatory effect of methylprednisolone on a protein level, IL-6 perfusate levels were measured over time and an interaction between time and treatment group was observed (P = 0.026). IL-6 perfusate levels increased over the perfusion period and from 3h onward, this increase was higher in the perfusate of untreated lungs from brain-dead donors than in the perfusate of methylprednisolone treated lungs (51 631.06 ± 34 635.20 pg/mL versus 17 067.59 ± 12 418.92 pg/mL after 6h of EVLP, P = 0.047, Figure 5F). All together, these results show that the
proinflammatory response in lungs from brain-dead donors is attenuated upon methylprednisolone treatment during EVLP.

**DISCUSSION**

In vivo methylprednisolone administration is a generally accepted treatment to improve lung quality during donor management. However, the wide effect range of methylprednisolone might be accompanied by adverse systemic side effects and the effect on quality of abdominal organs is debated.⁶,⁷ Therefore, methylprednisolone treatment in an isolated setting might be preferable. In this study, we aimed to investigate whether quality of lungs from brain-dead donors is improved upon ex vivo methylprednisolone treatment. We showed that BD-induced lung injury is attenuated upon methylprednisolone treatment during EVLP.

The improved Cdyn of lungs upon methylprednisolone treatment during EVLP probably reflects the impact of alveolar fluid clearance in the donor lung, as described before in literature.¹⁹ Although less edema was present upon methylprednisolone treatment in our study, this observation did not result in improved Pao₂/FiO₂ levels. Oxygenation status is traditionally considered most important when evaluating lung function. However, when measured in an acellular perfusate and open system during EVLP, the reliability of this test is questioned. Since only a few molecules of oxygen can significantly change Pao₂ values in plasma-like solutions, lung compliance is suggested as a more accurate parameter for assessing lung quality.²⁰ Methylprednisolone treatment during EVLP was suggested to limit a shift to anaerobic metabolism in our study, which possibly occurred in untreated lungs from brain-dead donors. Lactate levels are often used as a marker of poor prognosis and in clinically performed EVLP, in the presence of methylprednisolone, lactate levels are described to increase over time. However, it is suggested that this lactate increase represents physiologic lactate accumulation in a setting with reduced lactate clearance because lactate levels do not correlate with transplantation outcomes.²¹ Since a clinical comparative study with and without methylprednisolone treatment has not been performed, it is unknown whether lactate levels would be detrimentally increased in human EVLP lungs, in the absence of methylprednisolone. We speculate that the routine administration of methylprednisolone in clinically performed EVLP limits the BD-induced anaerobic shift. This theory might explain unsuitability for lactate as a marker of poor prognosis, in an EVLP setting in the presence of methylprednisolone.

The increase in inflammatory cells as suggested by histological injury scores of lungs from brain-dead donors...
compared to healthy donor lungs, probably reflect the earlier recruitment of inflammatory cells to the donor lung during the BD period. The ability of EVLP to wash out these donor-derived leukocytes into the perfusate has been described in the literature before. Yet in our model, the appearance of inflammatory cell influx after 6 h of EVLP was not decreased upon methylprednisolone treatment. Nevertheless, the downregulated levels of proinflammatory gene expressions upon...
methylprednisolone treatment during EVLP probably reflect an attenuated inflammatory state of the donor lung. Although Stone et al\textsuperscript{23} suggested that the technique of EVLP itself beneficially alters the inflammatory signaling profile of the donor lung, methylprednisolone might further contribute to the reduction of donor lung immunogenicity. Methylprednisolone is known to bind glucocorticoid receptors, which are present on most cells, including airway epithelial cells. Upon binding, activation of nuclear factor kappa B is inhibited and proinflammatory gene expression is blocked. Our findings are in line with methylprednisolone treated lungs as described by Martens et al\textsuperscript{24}, who studied the effect of methylprednisolone in a porcine model for donation after circulatory death (DCD) donors and showed a reduction in IL-1\textsuperscript{β} and TNF-\textalpha cytokine expression. Yet, it should be noted that the importance of the cytokine profile during acellular EVLP as a marker for lung injury has not yet been fully elucidated, since the absence of blood circulation or bone marrow in an EVLP circuit excludes the effect of recruited leukocytes.\textsuperscript{25} In contrast, when the lung is transplanted in a recipient with functioning bone marrow, elevated cytokine production is associated with poor graft function.\textsuperscript{26} In our study, BD-induced MCP-1 expression was downregulated by methylprednisolone treatment, which suggests diminished chemotraction of recruited macrophages. Macrophage count after methylprednisolone treatment during EVLP remained unaffected in our study (results not shown).

To our knowledge, comparative studies of EVLP with and without methylprednisolone treatment with a focus on quality of lungs from brain-dead donors, have not been performed before. Noda et al\textsuperscript{27} described their designed rat EVLP model for healthy donor lungs, and noted the necessity of methylprednisolone in the perfusate to establish a stable perfusion model. When methylprednisolone was omitted in their study, evident lung edema was noticed and perfusion for >1 h was not achieved. Martens et al\textsuperscript{24} showed in their porcine DCD model, that lung quality was improved upon methylprednisolone treatment during EVLP. In line with our findings, C\textsubscript{dyn} was ameliorated and oxygen status was unaffected in methylprednisolone treated lungs from DCD donors. However, it should be noted that the pathophysiological mechanisms of DCD donors eminently differ from brain-dead donors.\textsuperscript{28} Besides, in the mentioned study, methylprednisolone was administered in both the donor and during EVLP. Therefore, the exact effect of methylprednisolone during EVLP only remained unknown.

Although the strong point of our study is the specific focus on the effect of methylprednisolone on BD-related lung injury, a limitation is the absence of lung transplantation in our model. Whether methylprednisolone treatment during EVLP has an extended effect on recruited leukocytes associated with reperfusion injury, remains therefore unknown. In addition, it should be noticed that in our model, methylprednisolone treatment did not improve quality of lungs compared to baseline values, in accordance with previously described rat models for EVLP.\textsuperscript{27,29} We attribute the deterioration in quality over time in our model to the small organ size of rats. Given the fundamental differences in anatomy and physiology between small and large animal models or even human models, we believe that methylprednisolone treatment in large EVLP models might improve quality of lungs from brain-dead donors over time.\textsuperscript{30}

Methylprednisolone treatment has been applied from the very beginning of immunosuppression in lung transplantation, and remained a cornerstone in both donor management and recipient immunosuppressive strategies.\textsuperscript{31} Traditionally,
methylprednisolone is added to the EVLP perfusate, despite that its effect on BD-induced lung injury has not specifically been studied before. Before investigating new anti-inflammatory treatment modalities, we aimed to identify potentially confounding anti-inflammatory properties of methylprednisolone on BD-induced lung injury. The current, clinically applied EVLP strategy is described to significantly increase the amount of potential human donor lungs. However, other potential agents and particularly combined treatment strategies might even further enhance the quality of potential donor lungs. Most lung transplant recipients conventionally receive a triad of maintenance immunosuppression consisting of a calcineurin inhibitor, antiproliferative agent, and corticosteroid, with the goal to minimize immune-mediated injury to the donor lung. It might be suggested that donor lung preconditioning with this treatment triad additionally benefits donor lung quality. Haam et al already investigated the potential of the calcineurin inhibitor cyclosporine in preconditioning donor lungs during EVLP, and showed improved lung graft preservation due to anti-inflammatory and mitochondrial protective properties. Furthermore, new treatment strategies such as IL-10 gene therapy have been tested on the EVLP platform with positive results, which suggests that future donor lung optimization strategies may shift from general to a more specific approach.

In conclusion, this study contributes to the current knowledge on the potential of EVLP as a treatment platform, by showing that methylprednisolone treatment during EVLP attenuates BD-induced lung injury.

REFERENCES

1. Eurotransplant. Annual Report. 2019. Available at https://www.eurotransplant.org/wp-content/uploads/2020/06/Annual-Report-2019. pdf. Accessed July 23, 2020.
2. Avlonitis VS, Wigfield CH, Kirby JA, et al. The hemodynamic mechanisms of lung injury and systemic inflammatory response following brain death in the transplant donor. Am J Transplant. 2005;5(4 Pt 1):684–693.
3. Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011;364:1431–1440.
4. Follette DM, Rudich SM, Babcock WD. Improved oxygenation and increased lung donor recovery with high-dose steroid administration after brain death. J Heart Lung Transplant. 1998;17:423–429.
5. Dupuis S, Amiel JA, Desgroseillers M, et al. Corticosteroids in the management of brain-dead potential organ donors: a systematic review. Br J Anaesth. 2014;113:346–359.
6. van Erp AC, van Dullemen LFA, Ploeg RJ, et al. Systematic review on the treatment of deceased organ donors. Transplant Rev (Orlando). 2018;32:194–206.
7. Rebollodeo R, Liu B, Akhtar MZ, et al. Prednisolone has a positive effect on the kidney but not on the liver of brain dead rats: a potential role in complement activation. J Transl Med. 2014;12:111.
8. Dhar R, Cotton C, Coleman J, et al. Comparison of high- and low-dose corticosteroid regimens for organ donor management. J Crit Care. 2013;28:111.e1–111.e7.
9. Blasi-Ibanez A, Hirose R, Feiner J, et al. Predictors associated with terminal renal function in deceased organ donors in the intensive care unit. Anesth Analg. 2009;109:323–341.
10. Kolkert JL, ‘t Hart NA, van Dijk A, et al. The gradual onset brain death model: a relevant model to study organ donation and its consequences on the outcome after transplantation. Lab Anim. 2007;41:363–371.
11. Machuca TN, Cypel M. Ex vivo lung perfusion. J Thorac Dis. 2014;6:1054–1062.
12. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative Ct method. Nat Protoc. 2008;3:1101–1108.
13. Kappo J, Pelosi P, Tisiadigopoulos G, et al. Open lung approach associated with high-frequency oscillatory or low tidal volume mechanical ventilation improves respiratory function and minimizes lung injury in healthy and injured rats. Crit Care. 2010;14:R183.
14. De Backer D, Creteur J, Zhang H, et al. Lactate production by the lungs in acute lung injury. Am J Respir Crit Care Med. 1997;156(4 Pt 1):1095–1104.
15. Iacra F, Gullo A, Biolo G. Bench-to-bedside review: lactate and the lung. Crit Care. 2002;6:327–329.
16. Watts RP, Thom O, Fraser JF. Inflammatory signalling associated with brain dead organ donation: from brain injury to brain stem death and posttransplant ischaemia reperfusion injury. J Transplant. 2013;2013:521369.
17. Dannman J, Seelen MA, Moers C, et al. Systemic complement activation in deceased donors is associated with acute rejection after renal transplantation in the recipient. Transplantation. 2011;92:163–169.
18. Takada M, Nadeau KC, Hancock WW, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation. 1998;65:1533–1542.
19. Periman CE, Lederer DJ, Bhattacharya J. Micromechanisms of alveolar edema. Am J Respir Cell Mol Biol. 2011;44:34–39.
20. Yeung JC, Cypel M, Machuca TN, et al. Physiologic assessment of the ex vivo donor lung for transplantation. J Heart Lung Transplant. 2012;31:1120–1126.
21. Koike T, Yeung JC, Cypel M, et al. Kinetics of lactate metabolism during acellular normothermic ex vivo lung perfusion. J Heart Lung Transplant. 2011;30:1312–1319.
22. Stone JP, Critchley WJ, Major T, et al. Altered immunogenicity of donor lungs via removal of passenger leukocytes using ex vivo lung perfusion. Am J Transplant. 2016;16:33–43.
23. Stone JP, Ball AL, Orchilie W, et al. Ex vivo lung perfusion improves the inflammatory signaling profile of the porcine donor lung following transplantation. Transplantation. 2020;104:1899–1905.
24. Martens A, Boada M, Vanaudenaarde BM, et al. Steroids can reduce warm ischemic reperfusion injury in a porcine donation after circulatory death model with ex vivo lung perfusion evaluation. Transpl Int. 2016;29:1237–1246.
25. Sadaria MR, Smith PD, Fullerton DA, et al. Cytokine expression profile in human lungs undergoing normothermic ex-vivo lung perfusion. Ann Thorac Surg. 2011;92:478–484.
26. De Perrot M, Sekine Y, Fischer S, et al. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med. 2002;165:211–215.
27. Noda K, Shigemura N, Tanaka Y, et al. Successful prolonged ex vivo lung perfusion for graft preservation in rats. Eur J Cardiothorac Surg. 2014;45:e54–e60.
28. Dunne K, Doherty P. Donation after circulatory death. Contin Educ Anaesth Crit Care Pain. 2011;11:82–86.
29. Bassani GA, Lonati C, Brambilla D, et al. Ex vivo lung perfusion in the rat: detailed procedure and videos. PLoS One. 2016;11:e0167898.
30. Matute-Bello G, Frewert CW, Martin TR. Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2008;295:L379–L399.
31. Scheffert JL, Raza K. Immunosuppression in lung transplantation. J Thorac Dis. 2014;6:1039–1053.
32. Cypel M, Yeung JC, Donahoe L, et al. Normothermic ex vivo perfusion: does the indication impact organ utilization and patient outcomes after transplantation? J Thorac Cardiovasc Surg. 2020;159:346–355.e1.
33. Haam S, Noda K, Philips BJ, et al. Cyclosporin A administration during ex vivo lung perfusion preserves lung grafts in rat transplant model. Transplantation. 2020;104:e252–e259.
34. Machuca TN, Cypel M, Bonato R, et al. Safety and efficacy of ex vivo donor lung adenoviral IL-10 gene therapy in a large animal lung transplant survival model. Hum Gene Ther. 2017;28:757–765.